Mierke Johannes, Nowack Thomas, Loehn Tobias, Kluge Franziska, Poege Frederike, Speiser Uwe, Woitek Felix, Mangner Norman, Ibrahim Karim, Linke Axel, Pfluecke Christian
Technische Universität Dresden, Department of Internal Medicine and Cardiology, Herzzentrum Dresden, University Clinic, Dresden, Germany.
Kreiskrankenhaus Freiberg, Klinik für Innere Medizin II, Freiberg, Germany.
Int J Cardiol Heart Vasc. 2022 Mar 30;40:101013. doi: 10.1016/j.ijcha.2022.101013. eCollection 2022 Jun.
The APACHE II score assesses patient prognosis in intensive care units. Different disease entities are predictable by using a specific factor called Diagnostic Category Weight (DCW). We aimed to validate the prognostic value of the APACHE II score in patients treated with a percutaneous left ventricular assist device because of refractory cardiogenic shock (CS).
From the Dresden Impella Registry, we analyzed 180 patients receiving an Impella CP®. The main outcome was the observed intrahospital mortality ( ), which was compared to the predicted mortality estimated by the APACHE II score.
The APACHE II score, which was 33.5 ± 0.6, significantly overestimated intrahospital mortality ( 54.4 ± 3.7% vs. APACHE II 74.6 ± 1.6%; p < 0.001). Nevertheless, the APACHE II score showed an acceptable accuracy to predict intrahospital mortality (ROC AUC 0.70; 95% CI 0.62-0.78). Thus, we adapted the formula for calculation of predicted mortality by adjusting DCW. The total registry cohort was randomly divided into derivation group for calculation of adjusted DCW and validation group for testing. Intrahospital mortality was much more precisely predicted using the adjusted DCW compared to the conventional DCW (difference of predicted and observed mortality: -4.7 ± 2.4% vs. -23.2 ± 2.3%; p < 0.001). The new calculated DCW was -1.183 for the total cohort.
The APACHE II score has an acceptable accuracy for the prediction of intrahospital mortality but overestimates its total amount in CS patients. Adjustment of the DCW can lead to a much more precise prediction of prognosis.
急性生理与慢性健康状况评分系统(APACHE)II 用于评估重症监护病房患者的预后。通过使用一种称为诊断类别权重(DCW)的特定因素,可以预测不同的疾病实体。我们旨在验证因顽固性心源性休克(CS)接受经皮左心室辅助装置治疗的患者中 APACHE II 评分的预后价值。
从德累斯顿因佩拉注册中心,我们分析了 180 例接受 Impella CP®的患者。主要结局是观察到的院内死亡率( ),将其与 APACHE II 评分估计的预测死亡率进行比较。
APACHE II 评分为 33.5 ± 0.6,显著高估了院内死亡率( 54.4 ± 3.7% 对 APACHE II 74.6 ± 1.6%;p < 0.001)。然而,APACHE II 评分在预测院内死亡率方面显示出可接受的准确性(ROC 曲线下面积 0.70;95% 置信区间 0.62 - 0.78)。因此,我们通过调整 DCW 来调整预测死亡率的计算公式。将整个注册队列随机分为用于计算调整后 DCW 的推导组和用于测试的验证组。与传统 DCW 相比,使用调整后的 DCW 能更精确地预测院内死亡率(预测死亡率与观察死亡率的差异:-4.7 ± 2.4% 对 -23.2 ± 2.3%;p < 0.001)。整个队列新计算的 DCW 为 -1.183。
APACHE II 评分在预测院内死亡率方面具有可接受的准确性,但高估了 CS 患者的总体死亡率。调整 DCW 可导致对预后更精确的预测。